Gene Query: TUBA1A

Dataset Description Geneva Score
The regulation of ferroptosis by TAZ in epithelial ovarian cancer 151.15
IDH3a KO RNA-seq 148.15
RNA-sequencing of human mammary epithelial cells (HMLEs) engineered to express either ER or ER-SOX4 with and without 4-OHT to induce nuclear translocation 139.91
Nuclear Actin Regulates Inducible Transcription by Enhancing RNA Polymerase II Clustering 104.11
Comparing effects of perfusion and hydrostatic pressure on human chondrocytes using gene profiles 103.78
Dynamic incorporation of histone H3 variants into chromatin is essential for acquisition of aggressive traits and metastatic colonization 97.67
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L 96.44
Overexpression of PHF8 promotes an EMT-related gene signature in MCF10A cells 95.82
A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells 83.37
Transcriptome analysis of human immortilized astrocytes reprogrammed into dopaminergic neurons 81.18
Identifying lincRNA as prognostic biomarker for clear cell renal cell carcinoma 79.14
mRNA Sequencing of Human PromoCells Using 3'-directed Digital Gene Expression (3'-DGE) Technique 74.7
Identifying transcripts that are transcriptinoally regulated by CBFB and RUNX1 using RNAseq 73.58
Next generation sequencing of human hepatic stellate cell line, LX-2 treated with recombinant human TGF-β1, with DMSO or ML290 (5 µM) for 72h. 70.57
Analysis Of The TGFb-Induced Program In Primary Airway Epithelial Cells Shows Essential Role Of NF-kB/RelA Signaling Network In Type II Epithelial Mesenchymal Transition 69.83
Genome-wide analysis of herpes simplex virus type 1 (HSV-1) infected cells 69.56
Folate modulation induces chromosomal instability and higher proliferation of immortalized human keratinocytes 68.05
ZIKV infection of monocytes activates inflammasome pathways 65.81
Oncogenic Notch promotes long-range regulatory interactions within hyperconnected 3D cliques [HCC1599_RNA-seq] 65.78
Global transcriptomic analyses of bronchial epithelial cells exposed to 5 ng/mL TGF-β1 and 10 nM Estrogen individually and in combination 64.66
Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 62.46
Transcriptional profile of CAOV2 ovarian cancer cells with TAZ silencing 59.52
KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis 58.18
KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis [RNA-Seq] 58.18
Cell differentiation grade determines distinct FOXA2 contributions to the cis-regulatory networks of pancreatic cancer cells [RNA-seq] 57.02
Cell differentiation grade determines distinct FOXA2 contributions to the cis-regulatory networks of pancreatic cancer cells 57.02
RNA-seq analysis of SKMEL28 melanoma cells following DIRC3 and IGFBP5 ASO knockdown 54.91
UBR7 is a novel E3 ubiquitin ligase for H2BK120 and acts as a tumor-suppressor in breast cancer 54.56
UBR7 is a novel E3 ubiquitin ligase for H2BK120 and acts as a tumor-suppressor in breast cancer [RNA-Seq] 54.56
Paxillin regulates genomic networks in prostate cancer [LNCaP] 53.46
Improved LCL to iPSC reprogramming: RNA Analysis of LCLs, reprogrammed iPSCs, and differentiated NSCs reveal potential regulatory and functional processes involved in these cellular transitions. 52.43
Prostate Cancer Cell RNA-Seq (PC3E and GS689.Li) 51.97
Next generation sequencing on knockdown of AC093323.3 in lung cancer cells 51.5
Global analyses of the effect of different cellular contexts on microRNA targeting (RNA-Seq) 51.22
Global analyses of the effect of different cellular contexts on microRNA targeting 51.22
Transcriptome splicing analysis in K562 cells expressing rare and private spliceosomal mutations 49.39
ABCB5 is activated by MITF and b-catenin and is associated with melanoma differentiation 48.1
Transcriptome profiling identified a 3-lncRNA regulatory network in transthyretin against glucose induced hRECs dysfunction 47.87
Alternative splicing of differentiated myeloid cell transcripts after infection by Anaplasma phagocytophilum impacts a selective group of cellular programs 47.77
MARS Seq data from human cortical organoids 47.0
IGF2BP3 controls cancer cell invasiveness by modulation RISC function 46.71
Transcriptome profiling of Caki2 cells re-expressing Polybromo-1 (PBRM1) 46.43
Sequential regulatory loops as key gatekeepers for neuronal reprogramming in human cells [RNA-seq] 46.37
Sequential regulatory loops as key gatekeepers for neuronal reprogramming in human cells 46.37
Transcriptome analysis in HT29 and SW480 cells depleted of Prdx2 45.89
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma 45.8
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [RNA-seq] 45.8
microRNA suppresses prostate cancer stem cells and metastasis by inhibiting a cohort of pro-metastasis targets including CD44, Rho GTPases and EZH2 45.37
Genome-wide functional assessment of enhancer activities in the human genome 45.22
Synergy from Gene Expression and Network Mining (SynGeNet) method predicts genotype-specific synergistic drug combinations in melanoma 44.01
The role of FAM46C in myeloma cells [sequencing] 43.72
The role of FAM46C in myeloma cells 43.72
Identification of the networks that regulate human monocytic myeloid-derived suppressor cell differentiation into inflammatory macrophages 43.23
RNA-sequencing of human mammary epithelial cells (HMLEs) transduced in vitro with a shRNA against SOX4 or a scrambled shRNA in untreated and TGF-β-treated (16 hours) conditions 43.13
Analysis of the polyA+ RNA of LPS-treated human CD14+ monocytes 42.96
Human serum and heparin-free platelet lysate as appropriate xeno-free alternatives for production of human MuStem cell batches 42.47
Improved genome-wide mapping of uncapped and cleaved transcripts in eukaryotes—GMUCT 2.0 41.3
RNA-seq in transgenic cells 41.22
Loss of CREBBP results in H3K27Ac loss at enhancers and gene expression repression in lymphoma cells 40.76
Loss of CREBBP results in gene expression repression in lymphoma cells 40.76
Functional role of SLIT2 and ROBO1 in trophoblasts 40.44
Gene expression analysis of airway epithelial cells exposed to flagellin via RNA-seq 39.76
Gene expression analysis of airway epithelial cells exposed to flagellin via RNA-seq and microarray 39.76
Identification of the O-GlcNAc-regulated alternative splicing events by performing RNA sequencing on HeLa cells with altered O-GlcNAc level. 39.63
H19 regulates hepatic glucose production by epigenetic modification of Hnf4* 39.44
Identification of genes regulated by Long noncoding RNA H19 in hepatic cells 39.44
Transcriptome-wide analysis of IL2RA enhancer activation by CRISPRa 39.39
IQGAP3 interacts with Rad17 to activate the MRN/ATM/Chk2 signaling and promote radioresistance in lung cancer 38.81
Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition 37.8
Crizotinib v. DMSO in SW480 cells 37.62
Targets of CDK12 on ZR-75-30 breast cancer cells (RNA-seq) 37.35
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma (RNA-Seq) 37.33
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma 37.33
Differential RNA-seq analysis comparing APC-defective and APC-restored SW480 colorectal cancer cells 37.29
Gene expression profiling of LNCaP cells following shRNA-mediated knockdown of TMEFF2 and growth in presence and absence of dihydrotestosterone 37.18
Generation of induced keratinocyte stem cells from human urine cells by defined transcription factors 36.83
Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia (RNA-seq of KLF6 KO) 36.64
Mitochondrial 3243A > G mutation confers pro-atherogenic and pro-inflammatory properties in MELAS iPS derived endothelial cells 36.55
Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge 36.47
Gene expression profiling study by RNA-seq for identifying genes associated with epithelial-mesenchymal transition and acquired resistance to ALK inhibitors 36.42
Epithelial-mesenchymal transition and acquired resistance to ALK inhibitors 36.42
Effect of PRDM11 depletion in U2932 cells 35.78
Diverse Compounds from Pleuromutilin Lead to a Thioredoxin Inhibitor and Inducer of Ferroptosis 35.53
Retinoic acid suppresses MYB in adenoid cystic carcinoma [RNA-seq] 35.34
Retinoic acid suppresses MYB in adenoid cystic carcinoma 35.34
Analysis of transcriptional regulation by Myt1 and Myt1l 34.89
Expression profiling and occupancy after knockdown or over-expression of HFN1A or HNF4G in prostate cancer cells 34.89
Discovering the anti-cancer potential of non-oncology drugs by systematic PRISM profiling 34.41
Expression profile of HNF1A knockdown and overexpression in 22RV1 and LNCaP cells respectively 33.84
CD95L derived si- and shRNAs and the CD95L mRNA kill cancer cells through an RNAi mechanism by targeting survival genes [siL3.RNAseq.lg] 33.64
ZBTB48 is both a vertebrate telomere-binding protein and a transcriptional activator [RNA-seq] 33.55
ZBTB48 is both a vertebrate telomere-binding protein and a transcriptional activator 33.55
The effect of Abl kinases,or Ponatinib challenging on breast cancer cells' global transcriptome 33.4
Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer 33.2
Genetic-to-epigenetic Therapy for Pancreatic Cancer 33.14
CDK12 catalytic activity is rate-limiting for RNAPII processivity on core DNA replication genes and G1/S progression 32.52
Single-cell transcription profiling in KS1 patient iPSCs and NPCs 32.0
Cyclophosphamide (CTX) Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression 31.96
Differential expression of genes in HCMV-infected fibroblasts regulated by the purinergic receptor P2Y2. 31.87
Arginine methylation controls cell proliferation by integrating E2F activity with the splicing machinery (RNA-seq data set) 31.78
Arginine methylation controls cell proliferation by integrating E2F activity with the splicing machinery 31.78
Gene expression alterations associated with acquired-resistance to the CDK4/6 inhibitor palbociclib [Palbociclib resistance_RNASeq] 31.27
CT Irradiation Induced Changes of Gene Expression within Peripheral Blood Cells 31.06
Knock-down of Ror1 in MDA-MB-231 cell line decreases cell invasiveness 30.96
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer 30.75
KLF6-dependent transcription in renal cancer cells 30.65
EZH2 inhibitor efficacy in non-Hodgkin lymphoma does not require suppression of H3K27 mono-methylation 30.64
EZH2 inhibitor efficacy in non-Hodgkin lymphoma does not require suppression of H3K27 mono-methylation [RNA-Seq] 30.64
Human induced pluripotent stem cell-derived vocal fold mucosa mimics development and responses to smoke exposure 30.58
TMED9-gated CNIH4 and TGFa signaling promotes pro-metastatic states in human primary colon cancer cells 30.58
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence 30.4
mRNA expression profiling in MDA-MB-231 (LM1) cells with a tet-incible MBD2 or p66α knock down, or treated with MBD2-targeting small molecule ABA or APC 30.31
RNA seq with AML (NB4) cells upon FTO inhibition 29.81
TUT-DIS3L2 is a mammalian surveillance pathway for aberrant structured non-coding RNAs. 29.43
Uridylation-mediated RNA quality control pathway in mammalian cytoplasm [RNA-Seq] 29.43
Whole transcriptome RNA sequencing of human cells after HCV infection (ML-1 thyroid cell line, primary thyrocytes and Huh7.5 hepatocyte cell line) 29.28
A TFIID-SAGA perturbation that targets MYB and suppresses acute myeloid leukemia (RNA-seq) 29.21
A TFIID-SAGA perturbation that targets MYB and suppresses acute myeloid leukemia 29.21
Genetic and pharmacological restoration of TET2 function blocks stem cell self-renewal and progression of leukemia 29.08
RNA-sequencing of human leukemia cells and mouse hematopoietic progenitors 29.08
RNA sequencing of GLO1-depleted MDA-MB-231 breast cancer cells 28.91
Genome-wide maps of m6A circRNAs identify widespread and cell-type-specific methylation patterns that are distinct from mRNAs 28.6
Metabolic reprogramming of Kaposi’s sarcoma associated herpes virus infected B-cells in hypoxia 28.5
RNA sequence analysis of stable versus reversible EMT events and the resultant metastases 28.44
High-throughput sequencing of the human hepatic progenitor cell niche in PSC and HCV. 28.02
Global gene expression profile of human peripheral blood-derived endothelial colony-forming cells is similar to coronary artery and umbilical vein endothelial cells 28.02
RUNX1-ETO and RUNX1-EVI-1 differentially program the chromatin landscape in t(3;21) and t(8;21) AML but share global C/EBP-alpha dysfunction 27.8
RUNX1-ETO and RUNX1-EVI-1 differentially program the chromatin landscape in t(3;21) and t(8;21) AML but share global C/EBP-alpha dysfunction (RNA-Seq) 27.8
Consequences of Ribosomal Protein Haploinsufficiency in Human Hematopoiesis 27.63
U2AF1 mutations alter splice site recognition in hematological malignancies 27.59
Resistance to BET inhibitor leads to new therapeutic vulnerabilities in castration resistant prostate cancer 27.57
Replicated transcriptome profiling of Normal and Cancerous Prostate Cells [RNA-Seq] 27.5
Nutritional control of protein translation 27.46
Food-derived Compounds Apigenin and Luteolin Modulate mRNA Splicing of Introns with Weak Splice Sites 27.33
GATA2 promotes hematopoietic development and represses cardiac differentiation of human mesoderm 27.29
RNA-seq analysis of the role of HBO1 (KAT7/MYST2) in the ovarian cancer cell line UWB1.289. 27.23
An in vitro human liver model by iPSC-derived parenchymal and non-parenchymal cells 27.18
Montelukast counteracts the influenza virus-induced block in unfolded protein stress response and reduces virus multiplication 26.89
Genome-wide Dose-dependent Inhibition of Histone Deacetylases Reveals Their Roles in Enhancer Remodeling and Suppression of Oncogenic Super-enhancers 26.8
Inhibition of TNBC metastasis by Gpx1 26.74
Epigenomic landscape during organ formation in human early embryos 26.6
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. 26.6
Alu RNA modulates the expression of cell cycle genes in human fibroblasts 26.39
Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with Eralpha 26.36
Three-dimensional disorganisation of the cancer genome occurs coincident with long range genetic and epigenetic alterations 26.32
Three-dimensional disorganisation of the cancer genome occurs coincident with long range genetic and epigenetic alterations [RNA-seq] 26.32
Ribo_seq (aka ribosome profiling) analysis of control and Myc-induced U2OS cells 26.29
ARID1A regulates condensin II distribution and chromosomal partition 26.26
ARID1A regulates condensin II distribution and chromosomal partition [RNA-seq] 26.26
Acriflavine inhibits the epithelial-to-mesenchymal transition in vitro in liver and pancreatic cancer cells (part of study on PANC1 cells treated with CoCl2) 26.25
A novel lncRNA GAS1 promotes gastric carcinogenesis and acts as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern [RNA-seq] 26.23
ChIP-seq and RNA-seq in BGC823 cells after downregulation of GAS1 expression 26.23
A common cell state in Triple Negative Breast Cancers represents a druggable vulnerability 26.15
The effects of U1 snRNA mutation in chronic lymphocytic leukemia cell lines 25.97
Expression analysis of PC3 cells treated with scramble AON or AON directed against MBNL1 25.91
Transcriptome-wide study of the response of human trabecular meshwork cells to the substrate stiffness increase 25.65
mRNA cap methyltransferase, RNMT-RAM, promotes RNA pol II transcription 25.58
Transcriptional profile of CAOV2 primary and CAOV2 recurrent cells 25.56
Transcriptome Analysis of PBMCs in peripheral blood of patients with hepatocellular carcinoma 25.55
AMPK signaling for naïve pluripotency 25.49
AMPK signaling for naïve pluripotency [Hs] 25.49
Proteinase-Activated Receptor 4 (PAR4) mediates cell membrane blebbing in a Gaq/11, Gai independent, RhoA and ß-arrestin-dependent manner. 25.3
Transcriptional Regulationand Chromatin Dynamics inHuman Epithelial Cell Differentiation (RNA-seq) 25.11
Transcriptional Regulationand Chromatin Dynamics inHuman Epithelial Cell Differentiation 25.11
Mitochondrial hypoxic stress induces RNA editing by APOBEC3G in lymphocytes 25.03
Transcriptional profiles of human blood dendritic cell (DC) subsets at steady state 24.96
Stage-specific regulation of the WNT/β-catenin pathway enhances differentiation of hESCs into hepatocytes 24.92
NET-CAGE Characterizes the Dynamics and Topology of Human Transcribed Cis-regulatory Elements 24.65
RNA-Seq analysis of primary human keratinocytes exposed to Cannabidiol 24.64
RNA-seq data from human SGBS adipocytes differentiated with marine oxohexadecenoic acids 24.53
TAF1 is critical for AE driven leukemogenesis 24.5
TAF1 is critical for AE driven leukemogenesis [RNA-seq] 24.5
RNA-seq analysis of control and Myc-induced U2OS cells 24.47
Silencing p300 in MCF7 cells to study expression and alternative splicing 24.26
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (BRD4_JQ1_RNA-seq) 24.2
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression 24.2
PHF20 readers link methylation of histone H3K4 and p53 with H4K16 acetylation 24.19
RNA-sequencing of cells derived from the site of inflammation of Juvenile Idiopathic Arthritis patients 24.18
Epigenetic profiling and RNA-sequencing of Juvenile Idiopathic Arthritits (JIA) patients 24.18
Histone H3 Lysine4 Acetylation-Methylation Dynamics Define Breast Cancer Subtypes 24.03
Histone H3 lysine 4 acetylation-methylation dynamics define breast cancer subtypes [RNA-seq] 24.03
Targeting MTHFD2 in Acute Myeloid Leukemia 23.92
Transcriptomes of human monocytes after ex vivo exposure to uric acid 23.92
Codon usage optimization in pluripotent embryonic stem cells [tRNA sequencing] 23.9
Cis-Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer-Independent (RNA-seq) 23.79
Cis-Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer-Independent 23.79
Identification of an NKX3.1-G9a-UTY regulatory network that controls prostate differentiation 23.67
Identification of an NKX3.1-G9a-UTY regulatory network that controls prostate differentiation (Human_RWPE1_RNA-Seq) 23.67
Transcriptomes of human monocytes and monocyte-derived macrophages with or without glucocorticoid treatment 23.62
The effect of Foxc1 deficiency on undifferentiated and differentiated human primary keratinocytes 23.51
Inducible three-factor direct reprogramming to nephron progenitors using piggyBac transposons 23.47
Silencing SPIB in attached and floating state of H1703 lung cancer cells 23.14
DAOY-NERT2 Notch/Hypoxia Transcriptome Analysis 23.1
mRNA expression profile of A549 cells and MSR-A549 cells with or without JQ1 treatment 23.09
A549 cells and MSR-A549 cells 23.09
Gene expression changes associated with resistance to tagraxofusp (SL-401) 23.04
microRNAs with an AAGUGC seed motif constitute an integral part of a signaling network driving NSCLC cell proliferation 23.01
RNA-seq of ASXL2 shRNA KD in SKNO-1 cells 22.96
RNA-Seq Samples of siTFE3 in 8988T PDA Cell Line to Investigate Transcriptional Control of the Autophagy-Lysosome System 22.91
RNA-seq of MDA-MB-231 cells with TET1 knockout 22.85
Transcriptomic characterization of a human in vitro model of arrhythmogenic cardiomyopathy under topological and mechanical stimuli 22.84
Mediator kinase inhibition further activates super-enhancer-associated genes in AML 22.74
Effect in HCT116 cells of 3hr cortistatin A treatment on gene expression. 22.74
Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL [RNA-seq] 22.73
Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL 22.73
CD73 knockdown effect in pancreatic cancer cell lines 22.68
Identification of a unique subtype of lung squamous cell carcinoma defined by SOX2 and a neural differentiation factor BRN2 [RNA-seq] 22.63
Identification of a unique subtype of lung squamous cell carcinoma defined by SOX2 and a neural differentiation factor BRN2 22.63
Real-time observation of light-controlled transcription in living cells 22.61
Gene expression profiling associated with knockdown of RNF20 in human normal and malignant lung epithelial cell lines 22.57
Human SETMAR is a DNA sequence-specific histone-methylase with a broad effect on the transcriptome 22.55
Comparison between THP-1 cells obtained from either ATCC or DSMZ biorepository 22.52
TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma 22.49
Chromatin-informed inference of transcriptional programs in gynecologic cancers 22.37
Chromatin-informed inference of transcriptional programs in gynecologic cancers [RNA-Seq] 22.37
HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma 22.34
RNA-seq profiling of the human neutrophil genome during PMA- and E. coli encounter-induced activation 22.26
Human neutrophil genome during PMA- and E. coli encounter-induced activation 22.26
Control of prostate tumour growth by the long non-coding RNA GHSROS (LNCaP) 22.22
Genome-wide view of the impact of Spt5-Pol II inhibitors (SPIs) on mRNA levels [RNA-Seq 24h] 22.21
DNA breaks and chromatin structural changes enhance the transcription of Autoimmune Regulator target genes [RNA-Seq] 22.11
DNA breaks and chromatin structural changes enhance the transcription of Autoimmune Regulator target genes 22.11
Extensive remodeling of DC function by rapid maturation-induced epigenetic gene silencing 22.11
Extensive remodeling of DC function by rapid maturation-induced epigenetic gene silencing [RNA-Seq] 22.11
Molecular mechanism underlying increased ischemic damage in the ALDH2*2 genetic polymorphism using a human iPSC model system 22.04
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs with in vivo activity in hematological malignancies 22.01
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs with in vivo activity in hematological malignancies [RNA-Seq] 22.01
Integrative classification of human coding and non-coding genes based on RNA metabolism profiles 21.91
ETV4 is necessary for estrogen signaling and growth in endometrial cancer cells 21.83
ETV4 is necessary for estrogen signaling and growth in endometrial cancer cells [RNA-seq] 21.83
Effect of BMP inhibition or stimulation of primary human keratinocytes 21.83
Single-cell ID-seq identifies BMP signaling as a driver of a late stage epidermal differentiation program. 21.83
Triplet nucleotide repeat-based siRNAs are highly toxic to cancer cells 21.74
The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion 21.72
Estrogen deprivation triggers and immunosuppressive phenotype in breast cancer cells 21.7
Dynamic and stable enhancer-promoter contacts regulate terminal differentiation [RNA-Seq] 21.6
Dynamic and stable enhancer-promoter contacts regulate terminal differentiation 21.6
CBFb-SMMHC inhibition triggers apoptosis by disrupting MYC chromatin dynamics in acute myeloid leukemia [RNA-seq] 21.42
CBFb-SMMHC inhibition triggers apoptosis by disrupting MYC chromatin dynamics in acute myeloid leukemia 21.42
Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses (Experiment 1: RNA-seq) 21.42
A comprehensive single cell transcriptional landscape of human hematopoietic progenitors 21.41
RNA-seq analysis of SLIRP knockdown with 1nM DHT in LNCaP cells 21.36
An epigenetic mark of polycomb response elements implemented by Trx/MLL/COMPASS 21.32
Genome wide transcriptome analysis of palbociclib or GSK3326595 treated A375 cells [Palbociclib_GSK_RNASeq] 21.23
Integrative Analysis of Tamoxifen-resistant Cell Line Models Based on Sequencing Genomes, Transcriptomes and Epigenomes 21.22
Integrative Analysis of Tamoxifen-resistant Cell Line Models Based on Sequencing Genomes, Transcriptomes and Epigenomes [seq] 21.22
Transcriptomics analysis of gene expression in multiple human and mouse cells and tissues 21.22
AR-independent prostate cancer is sustained through FGF signaling 21.21
Transcriptome profiling of Normal and Cancerous Prostate Cells 21.21
Single-cell RNA-seq reveals novel cell differentiation dynamics during human airway epithelium regeneration 21.19
ZMYND8 reads the dual histone mark H3K4me1-H3K14ac to antagonize the expression of metastasis-linked genes 21.18
Altering cancer transcriptomes using epigenomic inhibitors [RNA-Seq] 20.96
Altering cancer transcriptomes using epigenomic inhibitors 20.96
RNA-seq analyses of human prostate cancer cells 20.89
Viral determinants in H5N1 influenza A virus enable productive infection of HeLa cells 20.69
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair 20.59
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia [inhibitor MRT199665] 20.48
Analysis of HPV16 E2 host gene expression using TERT immortalized keratinocytes (NOKs) cell lines and RNA-sequencing 20.46
Transcriptome of EMT induced MCF10A cells by TGFb treatment or SNAIL S6A expression. 20.44
Defining a microRNA-mRNA targetome for calcineurin inhibitor induced nephrotoxicity 20.43
Next generation sequencing analysis of transcriptomes at different timepoints after chlorprothixene treatment in NB4 and Kasumi-1 cells 20.43
The transcriptomic landscape of MAIT cell development in the thymus (NN41 RNAseq data set) 20.33
Transcriptome analysis of PC9 cells with gefitinib or/and hypoxia treatment and comparison with gefitinib resistant PC9 cells and ALDH positive PC9 cells 20.32
Expression profiles of restoration of BAP1 in a BAP1 deficient cell line 20.18
Transcriptome analysis of BAP1 knockout and restoration 20.18
A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression and cell death 20.11
RUNX1 contributes to higher-order chromatin organization and gene regulation in breast cancer cells. 20.1
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (RNAseq) 20.09
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination 20.09
RNA-seq of human foreskin fibroblast cells lacking RB and/or p130 after doxorubicin treatment 20.06
Detection of internal N7-methylguanosine (m7G) RNA modifications by mutational profiling sequencing 20.04
Hemogenic Endothelium transcriptome along the timeline of hESC differentiation 20.03
Targeting JNK Pathway Expands Human Hematopoietic Stem Cells 19.87
ER proteostasis and temperature differentially impact the mutational tolerance of influenza hemagglutinin 19.85
Apoptotic endothelial cells release small extracellular vesicles loaded with immunostimulatory viral-like RNAs 19.77
Effect of CTCF and Rad21 knockdown on SLK cells and KSHV gene expression 19.76
Gene Expression of Breast Cancer Cell Lines Across Biomaterial Platforms 19.74
Lineage specific differentiation is influenced by state of human pluripotency [RNA-seq] 19.74
Lineage specific differentiation is influenced by state of human pluripotency 19.74
Polyol pathway links glucose metabolism to the aggressiveness of cancer cells 19.73
Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML 19.72
RC3H1 posttranscriptionally regulates A20 mRNA and modulates the activity of the IKK/NF-kB pathway [RNA-Seq] 19.7
RC3H1 posttranscriptionally regulates A20 mRNA and modulates the activity of the IKK/NF-kB pathway 19.7
Super-enhancer-driven CCAT1 is co-activated by SOX2 and TP63 and promotes squamous cancer from esophagus, head and neck and lung [RNA-seq] 19.53
Super-enhancer-driven CCAT1 is co-activated by SOX2 and TP63 and promotes squamous cancer from esophagus, head and neck and lung 19.53
Plasma cell mitochondrial pyruvate import controls the duration of humoral immunity. 19.34
Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion 19.31
Oligogenic inheritance of congenital heart disease involving a NKX2-5 modifier 19.25
Oligogenic inheritance of congenital heart disease involving a NKX2-5 modifier [human] 19.25
A prostate cancer chromatin interaction map 18.96
mRNA Sequencing of Human PromoCells Using Random Primed mRNA-Sequencing Technique 18.78
Exploring ILF2 regulatory genes by next-generation sequencing 18.68
circRNA-sequencing 18.64
ChIP-seq and RNA-Seq analyses of epithelial and mesenchymal cells - HMLE, N8, N8-CTx 18.63
RNA-Seq comparisons of gene expression profiles of epithelial and mesenchymal cells - HMLE, N8, N8-CTx 18.63
Next Generation Sequencing upon siRNA-mediated knockdown of DRAIC in MCF-7 cells. 18.61
Transcriptome of EBV-infected gastric cancer cell lines 18.43
An Argonaute phosphorylation cycle promotes microRNA-mediated silencing [polyA RNA-seq] 18.41
RNA-sequencing of human peripheral blood mononuclear cells (PB MNCs) and induced neural progenitor cells derived from PB MNCs 18.4
Nucleoporin-mediated regulation of cell identity genes 18.38
GCTM-5 positive and negative cells in pancreatic adenocarcinoma cell lines 18.3
mRNA sequencing identifies differential gene expresssion profiles between ASCC3 knock-down cells and control cells 18.1
RNA sequence of mRNA in HUVEC cells after depleting EGFL6 17.99
Virus Mimicry in the Tumor Microenvironment Activates RIG-I Through Unshielding of Endogenous RNA in Exosomes [RNA-Seq] 17.96
Characterization of Type I Interferon pathway during Hepatic Differentiation of Human Pluripotent Stem Cells and hepatitis C virus infection 17.86
RNA-seq of MLLT3-overexpressing cultued HSPC, compared to non-overexpressing and uncutured FL-HSPC [RNAseq_MLLT3_OE] 17.54
Mllt3 Governs Self-Renewal And Engraftment Of Human Hematopoietic Stem Cells 17.54
Global gene expression profile of dasatinib-resistant RCH-ACV cells 17.54
Finding missing proteins from epigenetically manipulated human cells 17.38
RNA-Seq analysis of cSCC cells followed by siRNA-induced gene knockdown of C1s. 17.17
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (LNCaP RNA-seq) 17.16
The Adenovirus E1A C Terminus Suppresses a Delayed Antiviral Response and Modulates RAS Signaling [RNA-seq] 17.06
The Adenovirus E1A C Terminus Suppresses a Delayed Antiviral Response and Modulates RAS Signaling 17.06
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 16.98
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 16.98
IRF1 regulates IFN dependent and independent gene expression 16.92
Metastasis in triple negative breast cancer is dependent on ΔNp63/CXCL2/CCL22-mediated recruitment of myeloid-derived suppressor cells 16.9
The anti-leukemic effect of R-2HG depends on its acting as an m6A mRNA modifier-RNA Seq-PBS / R-2HG treatment 16.86
RNA-seq in HepG2 and IMR90 cells 16.86
Evolution of a transcriptional regulator from a transmembrane nucleoporin 16.86
Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer 16.77
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreas cancer 16.77
Generation of KRAS signatures using immortalized isogenic lung cells. 16.6
NF-κB p65 dimerization and DNA-binding is important for inflammatory gene expression 16.48
Transcriptomic Dynamics during Differentiation Process of Human Pluripotent Cells into Hepatocyte-like Cells 16.48
The NFkB subunit RELA is a master transcriptional regulator of the committed epithelial-mesenchymal transition in airway epithelial cells 16.46
Differential expression of long non‑coding RNA and mRNA in children with Henoch‑Schönlein purpura nephritis 16.27
A high-throughput screening strategy identifies regulators of alternative splicing via interaction with RNA G-quadruplexes 16.26
The Wnt/β-catenin and RAS-ERK Pathways were Activated in Tissues of Chemotherapy-Resistant Gastric Cancer PDX Tumor 16.16
Comparative analysis of mesenchymal stem cells derived from amniotic membrane, umbilical cord and chorionic plate under serum-free condition 15.85
RNA-seq and m6A-seq of AML cells with FTO knockdown or inhibition 15.83
Essential Roles of SETD7 as Transcriptional Activator and Co-regulator of H3K36me in Cardiac Lineage Commitment 15.81
RNA sequencing of human mammary epithelial cells 15.76
Transcriptome analysis of virus infected tissues 15.73
Differential Gene Expression between MCF10A and MCF7 cells 15.71
Identification of the RB loss-induced transcriptome and E2F1 cistrome in prostate cancer 15.57
Identification of the RB loss-induced transcriptome in prostate cancer [RNA] 15.57
Myeloid-derived suppressor cells facilitie invasion and metastasis of papillary thyroid cancer cells by repressing miR-486-3p 15.4
Transcriptome profiling of hnRNP A2/B1 and A1 depleted cells 15.35
A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism 15.23
Intron retention induced by microsatellite expansions as a disease biomarker. 15.15
Prediction of bacterial infection outcome using single cell RNA-seq analysis of human immune cells [sorted population Bulk RNA-seq] 15.11
Methylome, hydroxymethylome, and integrative transcriptome profiling in human CRC tissue and paired normal tissues 15.1
The effect of PPARG inhibition on human angiomyolipoma cells 15.09
RNA-seq after siRNA targeting DDX24 applied to iHUVECs cell lines 14.96
m6A-dependent regulation of messenger RNA stability 14.95
Tpl-2 and MEK small molecule inhibitors 14.9
Tpl-2 small molecule project 14.9
CDK12 inhibition in Hep3B, Huh7 and SNU449 cells 14.88
Platelet Transcriptome Profiling in HIV and ABCC4 as a Biomarker of Platelet Activity 14.85
Differential gene expression by suppression of either SOX2 or TP63 in KYSE70 human esophageal squamous carcinoma cell line. 14.84
Alternative splicing regulated by QKI and RBFOX1 promotes the mesenchymal cell state in breast cancer 14.62
RNA-sequencing in immortalized human mammary epithelial cells 14.62
Human lymph nodes maintain a unique subset of resident memory T cells with high functional potential important for protective immunity and immunotherapies 14.38
Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-FU-Mediated Cytotoxicity in Multiple Human Cancer Types 14.29
Thymine DNA Glycosylase as a novel target for melanoma: effect of TDG silencing on gene expression in SK-mel-28 melanoma cells 14.28
C9/ALS Human Embryonic Stem Cells and C9/ALS Induced Pluripotent Stem Cells 14.23
Mesenchymal stem/stromal cell engulfment reveals metastatic advantage in breast cancer 14.06
Disruption of Na+/H+ exchanger regulatory factor 2 scaffold suppresses colon cancer proliferation 13.87
Identification of Resistance Genes to BRAF Inhibitor in Melanoma by piggyBac Transposon Activation Mutagenesis Screen 13.76
RNA Seq analysis of NKX2-5 Null and Het human embryonic stem cells in cardiomyogenesis 13.52
Oncogenic changes and EMT in normal human bile duct epithelial cells are caused by parasite-derived materials and N-nitrosodimethylamine 13.51
Functional separation of IL7Rα/KLRG1-defined CD8+ T cell populations in humans 12.97
Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells 12.67
A bioinformatics approach reveals novel mechanisms of the OVOL transcription factors in the regulation of epithelial-mesenchymal cell programming and cancer progression. 12.62
Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples 12.6
MCF10A H-Ras RNA-Seq 12.42
shRNA-mediated knockdown of ETV4 and MED25 in the prostate cell line PC3 reveals set of genes potentially coregulated by MED25 and ETV4 12.41
Genome-wide occupancy of FLAG-MED25 and ETV4 and expression profiling of shRNA-mediated knockdown of ETV4 and MED25 in the prostate cell line PC3 12.41
mRNA sequencing of the mouse and human Hep-Orgs, Chol-Orgs and primary hepatocytes 12.22
RNA-seq of cells with TET1 knockout 11.97
An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer 11.96
An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer [RNA-Seq] 11.96
Time series single-cell transcriptomic analysis of AEC2 directed differentiation 11.95
SRSF1 role in cellular gene expression and splicing 11.92
Rate of elongation by RNA polymerase II is influenced by specific gene features and histone modifications 11.58
Exercise-induced transcriptome changes in skeletal muscle adapted to aerobic training 11.34
Repression of stress-induced LINE-1 expression protects cancer cell populations from lethal drug-exposures 11.12
Repression of stress-induced LINE-1 expression protects cancer cell populations from lethal drug-exposures [RNA-Seq] 11.12
RNA-seq transcriptonal profiling in human K562 cells with or without dCas9 and sgRNAs 11.09
In situ CAPTURE of chromatin interactions by biotinylated dCas9 11.09
GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 2) 11.08
SMAD2/3 are redirected to novel sites in MCF10A MII after prolonged TGFβ stimulation 10.94
JUNB is a critical AP1 component for SMAD2/3 binding after TGFβ stimulation [RNA-seq] 10.94
Nickel induced transcriptional changes persist post exposure through epigenetic reprograming (ChIP-seq & RNA-seq datasets) 10.9
miR-93 Targets in Human Endothelial Cells 10.87
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression [ELL2 KO] 10.82
Identification of PAX7-induced transcriptional changes and PAX7 genomic binding during skeletal myogenic differentiation of H9 embryonic stem cells 10.45
HMGA1 and FOXM1 synergistically regulate a common gene network modulating angiogenesis in breast cancer 10.25
SAM68 is required for regulation of Pumilio by the NORAD long noncoding RNA 10.24
IKZF1 as a Master Regulator of Immune Infiltrate Recruitment in Solid Tumors 9.86
Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids 9.84
Conservative alteration of chromosomal expression pattern across human solid tumor types 9.82
Expression alterations induced by restoration of AXIN1 expression in SNU449 hepatocellular carcinoma cells 9.4
Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice (human RNA-Seq) 9.34
KANK1 inhibits cell growth by inducing apoptosis though regulating CXXC5 in human malignant peripheral nerve sheath tumors 9.32
Expansion of adult human pancreatic tissue yields organoids harbouring progenitor cells with endocrine differentiation potential 9.25
RNA-sequencing analysis of glucose and acetate regulated transcripts in glioblastoma cells 9.11
RNA-seq of IL-4 stimulated human keratinocytes 8.92
RNA-seq analysis of human KMT2A rearranged MV4;11 AML cell line treated with DOT1L and/or EZH2 inhibitor 8.88
oxLDL exposed trained monocytes 8.76
Transcriptomes of oxLDL exposed trained monocytes 8.76
Alteration of the microRNA network during the progression of Alzheimer’s disease 8.66
RelA mutants 'reconstituted' and cell cycle synchronized HCT116 Colorectal Cancer Cells 8.63
Hyper-activation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2 8.51
6mer seed toxicity in tumour suppressive microRNAs 8.45
RNA-seq of cancer cell lines treated with T-025 8.42
RNA-Seq of Breast and Ovarian Cancer Cell Lines 8.4
Energy Metabolism during Anchorage-Independence 8.37
Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis 8.36
Ribosome profiling of TGFb-treated cells indicates reduced leucine availability 8.25
Changes in human endometrial gland transcriptome over the window of implantation 8.22
RNA-Seq expression profiling of hepatocellular carcinoma and adjacent non-tumor liver tissues 7.98
Gene expression patterns define the hepatocyte-like cells derived by different strategies [RNA-seq] 7.85
Gene expression patterns define the hepatocyte-like cells derived by different strategies 7.85
BASP1 modifies the Tamoxifen response 7.78
Comprehensive RNA sequencing of healthy human endometrium at two time points of the menstrual cycle 7.58
Genome-wide view of the impact of Spt5-Pol II inhibitors (SPIs) on mRNA levels [RNA-Seq 2h] 7.54
A comparison of gene expression between lesional and non-lesional derived keratinocytes of Hailey-Hailey disease patients. 7.4
Chronic Myeloid Leukemia (CML), induced pluripotent stem cell (iPSC)-derived lin-CD34+CD45+ (iCD34) cell population 7.26
Engineered Nanointerfaces for Microfluidic Isolation and Molecular Profiling of Tumor-specific Extracellular Vesicles 7.18
Total RNAseq of human putamen and caudate nucleus tissues in healthy control and Bipolar Disorder individuals 7.03
Estrogen Receptor Beta Impacts Hormone-Induced Alternative mRNA Splicing in Breast Cancer Cells 6.91
Whole transcriptome sequencing identifies increased CXCR2 expression in PNH granulocytes 6.91
Aberrant downstream mechanisms following loss of KMT2C and KMT2D in Pancreatic Ductal Adenocarcinoma 6.76
Transcriptome analysis of VCaP xenografts resistant to dual therapy with abiraterone and enzalutamide 6.63
Forkhead domain mutations in FOXA1 drive prostate cancer cell progression 6.55
RNA-seq in LNCaP cell line overexpressing WT or mutant FOXA1 6.55
RNA-seq analysis of Retinoic Acid and Non-treated Control hiPSCs 6.5
Transcriptome profiling of Cryptosporidium parvum infected lung and intestinal organoids 6.47
Epithelial-mesenchymal transition markers screenedina cell-based model and validated in lung adenocarcinoma 6.43
miR-191 regulates human cell proliferation and directly targets multiple oncogenes [seq] 6.33
Genome wide miR-191 target profile determined by RIP and gene expression profiling 6.33
Loss of ANCO1 repression of AIB1/YAP drives breast cancer progression 6.29
Induction of extracellular adenosine salvage and metabolic quiescence regulate the transitional to follicular B cell checkpoint in humans. 6.19
RNA-sequencing transcriptome profiling of normal human keratinocytes differentiation 6.14
Modulation of mitochondrial DNA copy number to induce hepatocytic differentiation of human Amniotic Epithelial cells 5.98
CDK12 regulates alternative last exon mRNA splicing and promotes invasion of a breast cancer cell line 5.86
A single-cell transcriptome atlas of the human pancreas 5.84
SREBP1 drives Keratin 80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ERα breast cancer 5.8
Transcriptional profiling of healthy, eutopic and ectopic endometrial organoids 5.71
CDK4/6 inhibitor resistance in prostate cancer 5.63
Illumina Human Polycystic Liver Disease and Normal Biliary Stem Cell RNAseq 5.6
The interplay between SOX4 and SMAD3 in the context of breast cancer 5.56
RNA seq_PDX2_SHP099 5.53
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma 5.49
Host transcriptome analysis of Aspergillus fumigatus infection in Airway Epithelial Cells 5.45
Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells 5.3
Multiple roles for Grainyheadlike transcription factors in the establishment and maintenance of human mucociliary airway epithelium 5.23
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia [mutant MEF2C] 5.16
Transcriptomic analysis of the role of the integrin a6b4 in detached cells 4.84
Human colon organoids reveal distinct physiologic and oncogenic Wnt responses 4.83
MBNL1-dependent modulation of gene expression in MDA-MB-231 breast cancer cells 4.5
Muscleblind-like 1 suppresses breast cancer metastatic colonization and stabilizes metastasis suppressor transcripts 4.5
Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance 4.5
Co-regulation of transcription by BRG1 and Brm, two mutually exclusive SWI/SNF ATPase subunits 4.5
Cooperative and Antagonistic Transcriptional Regulation by BRG/BRM [RNA-seq] 4.5
Analysis of gene expression in primary human foreskin keratinocytes +/- HPV16 E7 or PTPN14 knockout 4.24
Genes altered in expression by Cisplatin treatment in lung cancer cell lines 4.08
Next Generation Sequencing and m6A sequencing Facilitates Quantitative Analysis of Wild Type and genetic FTO knockdown ccRCC cells Transcriptomes 3.94
m6A-RNA mapping, SND1-RNA binding profile mapping and SND1-depletion in KSHV-infected B-lymphocytes 3.86
Sequencing of ponatinib-resistant LC-2/ad derivatives (PR1 and PR2) and parental LC-2/ad cells 3.83
Gene expression profiles of isogenic single-cell derived clones of BRAF-mutated SK-MEL-5 melanoma cell lines 3.76
β-catenin/Tcf7l2 dependent transcriptional regulation of GLUT1 gene expression by Zic family proteins in colon cancer 3.75
Characterizing smoking-induced transcriptional heterogeneity in the human bronchial epithelium at single-cell resolution 3.56
Gene expression analysis of human liver progenitor-like cells in culture 3.42
Transcriptomic analysis of inter- and intra-patient variation in human iPSC cardiomyocytes: Platform for precision medicine to predict drug toxicity 3.4
Combined MEKi (GDC-0973) and WNT (G007-LK) treatment in APC and KRAS mutant HCT-15 cell line 3.33
RNA-Seq analysis of cSCC cells followed by siRNA-induced gene knockdown of AIM2. 3.27
Dissecting the single-cell transcriptome network underlying gastric premalignant lesions and early gastric cancer [10x genomics] 3.25
Expression profile of wild type (WT) vs miR-155-/- in FLT3-ITD+ AML (MV4-11) cell lines 3.19
Genome-wide CRISPR-Cas9 screen identifies functionally relevant microRNAs in AML 3.19
Tafazzin Regulates Cell State by Modulating Phosphatidylethanolamine and Phosphatidylserine levels 3.09
Paclitaxel plus Cirmtuzumab Achieves Greater Clearance of Patient-derived Xenografts By Targeting ROR1+ Breast Cancer Stem Cells 3.05
Differential gene expression of human melanoma cells [RNA-seq] 2.98
GDF6-induced BMP signaling reawakens a neural crest identity in melanoma to prevent cell death and differentiation 2.98
Regulation of poly(A) tail and translation during the somatic cell cycle 2.95
Transcriptome sequencing of K-562 cells 2.94
Effects of plasticizers (bisphenol A, bisphenol AF) and an herbicide in MCF7 human breast cancer cells 2.58
Fbxo32 mediated gene expression program underlies EMT and metastasis 2.55
Characterization of human CDK12 and CDK13 in the regulation of RNA processing 2.21
6mer seed toxicity in viral microRNAs 2.2
Parallel T-cell cloning and deep sequencing of the transcripts of human MAIT cells reveal stable oligoclonal TCRβ repertoire 1.92
CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops 1.87
Disease-associated mutation in SRSF2 misregulates splicing by altering RNA binding affinities 1.52
mRNA sequencing of oropharyngeal cancer cell lines 1.5
Elongation Factor TFIIS Prevents Transcription Stress and R-Loop Accumulation to Maintain Genome Stability 1.36
Elongation Factor TFIIS Prevents Transcription Stress and R-Loop Accumulation to Maintain Genome Stability [ RNA-seq] 1.36
Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α 1.25
Similarity of therapeutic networks induced by a multi-component herbal remedy in neurovascular unit cells 1.23
Characterisation of the EZH2 regulated transcriptome in de novo transformed cells (RNA-Seq) 0.98
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas 0.85
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas [RNA-seq] 0.85
Longitudinal transcriptome profiling of post-treatment Lyme disease syndrome 0.8
Characterization of the Merkel cell carcinoma miRNome 0.77
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies 0.52
Neural cell adhesion molecule 1 (NCAM1; CD56) promotes leukemogenesis and confers drug resistance in acute myeloid leukemia. 0.42
The impact of oil spill to lung health – insights from an RNA-seq study of human airway epithelial cells 0.35
Inhibition of H3K4 demethylation induces autophagy in cancer cell lines 0.16
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors 0.08


Contact Us

For scientific and technical queries contact Butte Lab @UCSF


Cite GENEVA Tool

Manuscript in Preparation